https://retina.news.mail.ru/prev780x440/pic/0d/11/main42036797_d327d47fd056b174984e5e57a7b61785.jpg

MOSCOW, 3 Dec — RIA Novosti. national research center of epidemiology and Microbiology named Gamalei and the defense Ministry by the end of July to complete all clinical trials of a vaccine against COVID-19, said Wednesday the chief of the 48th Central research Institute (TSNII) of the military Department Sergey Borisevich in an interview with the newspaper “Red star”.

Preclinical tests of the vaccine have already been completed, he said. Within them were studies in monkeys and hamsters.

“During the studies have shown and proven the drug’s safety and protective efficacy. The results of these studies prepared scientific and technical documentation for obtaining permits to conduct clinical trials,” — said head of 48th Central research Institute.

In turn, the head of the Main military clinical hospital named after academician N. N. Burdenko major General medical services Eugene Kryukov said that the volunteers who participate in vaccine trials from COVID-19, should be by contract servicemen.

He said that among 50 volunteers to test the vaccine ten medical workers, including three doctors.

“All the candidates, in addition to the consent for voluntary participation in research work, had to provide supporting documents about the absence of chronic diseases, including cancer, which can complicate the conduct of clinical trials,” — said the head of the hospital.

on Tuesday, the defense Ministry said that the vaccine trials will be conducted on the basis of the 48th Central research Institute. The arrival of the first group military volunteers to the hospital for examination and preparation for the experiment to test a vaccine will be held June 3.

Previously, the General Director of the Novosibirsk scientific center “Vector” Rinat Maksyutov told in the film naili Asker-zade “Threat virus. The vaccine” on TV channel “Russia 1”, which experts have developed a vaccine that can be instilled into the nose. It has already experienced in the lower primates, the animals responded well to the introduction drugs, no side effects were not.

the First clinical study on humans will begin in late June — early July. Conducted clinical trials will be volunteers of both sexes aged 18 to 60 years, has continued the General Director of “Vector”. The people, already ill COVID-19, volunteers become unable to.